Finally, in-depth research shows that SAL interrupts HIF-1α/VEGF signaling for inhibiting angiogenesis and BC growth induced by VEGF, and is a promising antiangiogenic agent for treating BC [68]. The gene discussed is HIF1A; the disease is breast cancer.